Epidermal Growth Factor Receptor, p53 Mutation, and Pathological Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Preoperative Chemoradiotherapy

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6461-6468

  Gibson, Michael K ^a   Abraham, Susan C ^b   Wu, Tsung Teh ^c   Burtness, Barbara ^d   Heitmiller, Richard F ^e   Heath, Elisabeth ^a   Forastiere, Arlene ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNION MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA SEQUENCE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

ADENOCARCINOMA; AGED; BCL-2-ASSOCIATED X PROTEIN; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0346963103     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
3. Forastiere, A. A., Heitmiller, R. F., Lee, D. J., Zahurak, M., Abrams, R., Kleinberg, L., Watkins, S., Yeo, C. J., Lillemoe, K. D., Sitzmann, J. V., and Sharfman, W. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J. Sci. Am., 3: 144-152, 1997.
4. Heath, E. I., Burtness, B. A., Heitmiller, R. F., Salem, R., Kleinberg, L., Knisely, J. P., Yang, S. C., Talamini, M. A., Kaufman, H. S., Canto, M. I., Topazian, M., Wu, T. T., Olukayode, K., and Forastiere, A. A. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J. Clin. Oncol., 18: 868-876, 2000.
5. Kleinberg, L., Knisely, J. P., Heitmiller, E. S., Zahurak, M., Salem, R., Burtness, B. A., Heath, E., and Forastiere, A. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys., 56: 328-334, 2003.
6. Salazar, J. D., Doty, J. R., Lin, J. W., Dyke, M. C., Roberts, J., Heitmiller, E. S., and Heitmiller, R. F. Does cell type influence postesophagectomy survival in patients with esophageal cancer? Dis. Esophagus, 11: 168-171, 1998.
7. Bosset, J. F., Gignoux, M., Triboulet, J. P., Tiret, E., Mantion, G., Elias, D., Lozach, P., Ollier, J. C., Pavy, J. J., Mercier, M., and Sahmoud, T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N. Engl. J. Med., 337: 161-167, 1997.
8. Kelsen, D. P., Ginsberg, R., Pajak, T. F., Sheahan, D. G., Gunderson, L., Mortimer, J., Estes, N., Haller, D. G., Ajani, J., Kocha, W., Minsky, B. D., and Roth, J. A. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med., 339: 1979-1984, 1998.
9. Urba, S. G., Orringer, M. B., Turrisi, A., Iannettoni, M., Forastiere, A., and Strawderman, M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol., 19: 305-313, 2001.
10. Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., and Hennessy, T. P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med., 335: 462-467, 1996.
11. Forastiere, A. A., Heitmiller, R. F., and Kleinberg, L. Multimodality therapy for esophageal cancer. Chest, 112: 195S-200S, 1997.
12. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
13. Walsh, T. N., Grannell, M., and Mansoor, S. Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. J. Gastroenterol. Hepatol., 17 (Suppl): S172-S175, 2002.
14. Harpole, D. H., Jr., Moore, M. B., Herndon, J. E., 2nd, Aloia, T., D'Amico, T. A., Sporn, T., Parr, A., Linoila, I., and Allegra, C. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res., 7: 562-569, 2001.
15. Ribeiro, U., Jr., Finkelstein, S. D., Safatle-Ribeiro, A. V., Landreneau, R. J., Clarke, M. R., Bakker, A., Swalsky, P. A., Gooding, W. E., and Posner, M. C. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer (Phila.), 83: 7-18, 1998.
16. Muro, K., Ohtsu, A., Boku, N., Chin, K., Oda, Y., Fujii, T., Hosokawa, K., Yoshida, S., and Hasebe, T. Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn. J. Clin. Oncol., 26: 65-69, 1996.
17. Hickey, K., Grehan, D., Reid, I. M., O'Briain, S., Walsh, T. N., and Hennessy, T. P. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer (Phila.), 74: 1693-1698, 1994.
18. Brown, L. M., and Devesa, S. S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am., 11: 235-256, 2002.
19. Devesa, S. S., Blot, W. J., and Fraumeni, J. F., Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (Phila.), 83: 2049-2053, 1998.
20. Keller, J. J., Offerhaus, G. J., Polak, M., Goodman, S. N., Zahurak, M. L., Hylind, L. M., Hamilton, S. R., and Giardiello, F. M. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut, 45: 822-828, 1999.
21. Slebos, R. J., Baas, I. O., Clement, M., Polak, M., Mulder, J. W., van den Berg, F. M., Hamilton, S. R., and Offerhaus, G. J. Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. Br. J. Cancer, 74: 165-171, 1996.
22. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
23. Posner, M. C., Gooding, W. E., Lew, J. I., Rosenstein, M. M., and Lembersky, B. C. Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer. Surgery, 130: 620-626; discussion 626-628, 2001.
24. Wolfe, W. G., Vaughn, A. L., Seigler, H. F., Hathorn, J. W., Leopold, K. A., and Duhaylongsod, F. G. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J. Thorac. Cardiovasc. Surg., 105: 749-755; discussion 755-746, 1993.
25. Ito, T., Kaneko, K., Makino, R., Ito, H., Konishi, K., Kurahashi, T., Kitahara, T., and Mitamura, K. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J. Gastroenterol., 36: 303-311, 2001.
26. Hahn, W. C., and Weinberg, R. A. Rules for making human tumor cells. N. Engl. J. Med., 347: 1593-1603, 2002.
27. Johnstone. R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
28. Dumont, P., Leu, J. I., Della Pietra, A. C. III, George, D. L., and Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33: 357-365, 2003.
29. Ross, J. S., and McKenna, B. J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investig., 19: 554-568, 2001.
30. Grandis, J. R., Melhem, M. F., Barnes, E. L., and Tweardy, D. J. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (Phila.), 78: 1284-1292, 1996.
31. Scambia, G., Panici, P. B., Battaglia, F., Ferrandina, G., Almadori, G., Paludetti, G., Maurizi, M., and Mancuso, S. Receptors for epidermal growth factor and steroid hormones in primary laryngeal tumors. Cancer (Phila.), 67: 1347-1351, 1991.
32. al-Kasspooles, M., Moore, J. H., Orringer, M. B., and Beer, D. G. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer, 54: 213-219, 1993.
33. Nicholson, R. I., Gee, J. M., and Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer, 37 (Suppl 4): S9-S15, 2001.
34. Aloia, T. A., Harpole, D. H., Jr., Reed, C. E., Allegra, C., Moore, M. B., Herndon, J. E. II, and D'Amico, T. A. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann. Thorac. Surg., 72: 859-866, 2001.
35. Hirai, T., Kuwahara, M., Yoshida, K., Kagawa, Y., Hihara, J., Yamashita, Y., and Toge, T. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis. Esophagus, 11: 221-225, 1998.
36. Itakura, Y., Sasano, H., Shiga, C., Furukawa, Y., Shiga, K., Mori, S., and Nagura, H. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer (Phila.), 74: 795-804, 1994.
37. Yacoub, L., Goldman, H., and Odze, R. D. Transforming growth factor-αa, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod. Pathol., 10: 105-112, 1997.
38. Ozawa, S., Ueda, M., Ando, N., Shimizu, N., and Abe, O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer (Phila.), 63: 2169-2173, 1989.
39. Mukaida, H., Toi, M., Hirai, T., Yamashita, Y., and Toge, T. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer (Phila.), 68: 142-148, 1991.
40. Kitagawa, Y., Ueda, M., Ando, N., Ozawa, S., Shimizu, N., and Kitajima, M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 2: 909-914, 1996.